To understand the medicines use patterns to treat patients with bipolar disorder type I. This is the aim of the most recent study of Evidências - Kantar Health published in an international journal. The article “Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA” was released by the Dovepress Journal, a prestigious journal in science and medicine. Luciano Paladini, Teresa Lemmer, and Otávio Clark, from the Evidências – Kantar Health team, conducted the study in partnership with a global client.
Bipolar disorder is a mental illness that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Bipolar disorder type I (BD-I) is a chronic condition characterized by periods of severe mood episodes from mania to depression. It is a life-long condition and, thus, requires long-term pharmacological treatment.
A systematic literature review was performed in MEDLINE and Embase databases searching for data on therapies and adherence to medications in type I bipolar disorder. The results showed that treatment prevalence for bipolar disorder type I in the USA, and that from 30% to 60% of patients with the disease do not receive appropriate treatment.
The article demonstrated that there is a need for studies specifically addressing patterns of therapy and adherence to pharmacological treatment in patients with type I bipolar disorder. This would help to better plan healthcare policies and improve adherence and persistence rates for bipolar disorder.
The study can be read at this link.